In-Depth Examination Of 11 Analyst Recommendations For 10x Genomics
Portfolio Pulse from Benzinga Insights
11 analysts have recently evaluated 10x Genomics (NASDAQ:TXG), showing mixed sentiments. The average 12-month price target has decreased by 32.5% to $27.0. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Despite a strong revenue growth rate of 4.28%, 10x Genomics faces challenges with negative net margin, ROE, and ROA, but maintains a low debt-to-equity ratio.
September 03, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have mixed views on 10x Genomics, with a significant drop in the average price target to $27.0. Despite strong revenue growth, the company faces challenges with negative net margin, ROE, and ROA. The low debt-to-equity ratio is a positive aspect.
The decrease in the average price target by 32.5% indicates a bearish sentiment among analysts. Despite the company's strong revenue growth, the negative net margin, ROE, and ROA suggest financial challenges. The low debt-to-equity ratio is a positive factor but may not offset the negative aspects in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100